The 4 year prospective trial on the effectiveness of the antihypertensive treatment was performed in 100 mild hypertensive patients of the aged, the average age being 76.1 years. Dropouts during the drug-off control period were 9 cases. The matched pair group was selected by the age, sex, and blood pressure. Forty-four drug treated cases and 47 placebo treated cases were comparable in blood pressure as well as in laboratory data.
the cerebral or coronary blood flow, and induce ischemia of the target organs.3) However, it is also known that hypertension in the elderly shows the higher prevalence of cerebral or cardiovascular complications, and the lower survival rate than the normotensive group.4), 5) In order to evaluate the effectiveness of the long term antihypertensive treatment in the mild hypertension of the aged, prospective trial was performed by comparing the drug treated group with the placebo treated group of matched pair subjects.
METHODS
One hundred patients enrolled in the study were residents of the Tokyo Metropolitan Homes for the aged, and showed normal activity of daily living without complications. The previous antihypertensive medications were withdrawn and switched to the placebo, and the blood pressure reached a new level in a month.6) The patients with blood pressure of more than 160/90 and less than 200/110mmHg were included in the study. The matched pair group was selected by the age, sex, and blood pressure levels during the drug-off control period of about 1 year. During this control period 9 patients were dropped out because of blood pressure elevation in 6, and one each of cerebral bleeding, cholelithiasis, and moving out. Thus, remaining 91 patients were divided into 44 of the drug treated group and 47 of the placebo treated group. Average ages of male patients in each group were 74.9 and 75.7 years, and those of female patients were 76.3 and 77.9 years respectively (Table  I) .
Patients were followed up once or twice a month for 4 years from 1975 to 1979. Patients were excluded from the trial when the blood pressure exceeded 200/110, and appearance of cerebrovascular or cardiac complications, other diseases which needed hospital admission, death, or moving out from the Home were considered to be the dropout.
In the drug treated group thiazide diuretics (trichlormethiazide 1 to 4mg) were used as basal antihypertensive drugs. Thiazide monotherapy was used in 35 cases out of 44 cases. In the remaining 9 cases reserpine (0.3mg), methyldopa (125 to 500mg), and hydralazine (50 to 100mg) were added by stepped care approach when needed. 
RESULTS
Blood pressure and laboratory data in the control period: The blood pressure level and laboratory data during the control period are shown in Table II . Average blood pressures were 166.1/85.5 4.3/2.2 mmHg in the placebo group, and 171.3/86.5 4.2/1.9mmHg in the drug group, and showed no significant difference. The systolic blood pressure was between 160 and 200mmHg, but the diastolic blood pressure of 90mmHg or over was found in 56.0%.of total subjects, 57.4% in the placebo group and 54.6% in the drug group. In laboratory data cholesterol levels were 175.4 mg/100ml in the placebo group and 173.0mg/100ml in the drug group. Blood urea nitrogens were 19.0 and 18.0mg/100ml, uric acids were 5.2 and 5.5mg/100ml, hemoglobin concentrations were 13.0 and 12.9Gm/100ml, cardiothoracic ratios in chest X-ray were 55.3 and 56.3%, ECG scores for LVH were 1.1 and 1.3 respectively. By all factors measured the 2 groups were considered to be comparable.
Cerebro-cardiovascular and other complications during the 4 year trial period: The cerebrovascular and cardiac complications observed during the 4 year prospective trial are shown in Table III . Six cases of dropout due to moving out from the Home were observed in both groups, and follow up cases were 38 in the drug group and 41 in the placebo group. The mortal events in the drug group were one each of cerebral infarction, cerebral hemorrhage and sudden death, and deaths in the placebo group were 1 case of cerebral infarction and 2 cases of myocardial infarction. The morbid events which needed hospital admission in the drug group were 1 case of cerebral infarction, and in the placebo group 2 cases of cerebral infarction and 2 cases of congestive heart failure with arrhythmia were observed. The morbid events which were treated at outpatient deparment were one each of cerebral infarction and congestive heart failure with arrhythmia. As a whole 9 out of 41 cases or 22.0% in the placebo group, and 4 out of 38 cases or 10.5% in the drug group dropped out by cerebrovascular or cardiac complications. This difference was not significant statistically. In addition to the cerebrovascular and cardiac complications dropouts due to blood pressure elevation were observed in 8 cases in the placebo group, and total dropouts in the placebo group were 17 cases or 41.5%. This incidence was significartly higher than that in the drug treat- (Table IV) . Other complications were observed in 12 cases or 31.6% in the drug group, and in 17 cases or 41.5% in the placebo group. These were not different significantly. Therefore, cases without events were 22 cases or 57.9% in the drug group, and 7 cases or 17.1% in the placebo group showing a significant difference. Other complications are shown in Table V . Four deaths in the drug group were due to cancers of the stomach, lung and gall bladder, and 4 deaths in the placebo group were caused by pneumonia, miliary tuberculosis, and cancer of the esophagus. Morbid events were observed in 8 cases in the drug group and in 13 cases in the placebo group. Major causes for admission in these patients were bone and joint diseases, cancer, psychiatric disorder, infections, prostate hypertrophy, and others. It should be noticed that these events were 2 or 3 times higher than that of the cerebrovascular and cardiac complications.
Course of blood pressure in the drug and placebo groups: The trends of mean blood pressure at each month are shown in Fig. 1 number of the follow up cases at the end of each year declined from 44 to 32 , 26, 25, and 22 due to dropouts. Blood pressure in the placebo group changed little from 166/86 to 167/86 in the first year, but gradually declined to 162/82 in the second year, 159/80 in the third year, and 150/78 in the fourth year due to dropouts of the hypertensive cases. The number of the follow up cases in the placebo group decreased markedly from 47 to 32 , 24, 13, and 7 at the end of each year. In 22 cases of the drug group followed up through 4 year trial period blood pressure declined from 171/87 to 162/84, 154/80, 152/80, and 150/79 in each year, and the average decrease was 21/8mmHg (Fig . 2) . In 7 cases of placebo group the blood pressure during the control period was relatively low and gradually declined in the placebo period probably due to aging.
The blood pressures before the onset of cerebrovascular or cardiac complications in the drug treated patients oscillated arround 140/80, and no abrupt changes were observed. Blood pressures in the 9 placebo treated patients were fluctuated in the higher level, but no trend of elevation was observed.
Laboratory data during the trial period: Changes in laboratory data in 16 thiazide trated patients and 11 placebo treated patients are shown in Fig. 3 . Hematocrit, serum protein, urea nitrogen, uric acid, sodium, and potassium for 3 year trial period revealed no sign- igicant changes. The uric acid in thiazide treated group was slightly elevated from 5.5 to 6.2mg/100ml, but not different signigicantly .
DISCUSSION
The present prospective study revealed that antihypertensive treatment in the elderly with mild hypertension was effective in decreasing the cerebrovascular and cardiac complications when elevation of blood pressure was counted as a dropout. The cerebrovascular and cardiac complications were observed in 10.5% in the drug treated group, and in 22 .0% in the placebo group. This difference was not significant probably due to the small number of the cases. When blood pressure elevation in the placebo group were added to the complications, dropouts in the placebo group reached 41.5%. This showed the significant difference. However, other complications such as cancers, bone or joint diseases, infections, psychiatric disorders were 2 or 3 times more prevalent than cerebro-cardiovascular complications .
There has been no general agreement on the effect of the antihypertensive treatment in the elderly. The negative aspect on the antihypertensive therapy was propsed by Fry.1) He observed the natural history of hypertension and found no increasing mortality rates with rising blood pressure in the over-sixties. Carter2) followed up 99 cases of diastolic pressure over 110 mmHg for 2 to 5 years, and found the stroke recurrence to be 44% in placebo group, and 20% in drug terated group, but found no beneficial effect on the mortality over the age of 65. Jackson et al3) presented the 6 symptomless hypertensive cases aged 64 to 84 who revealed unconsciousness and residual symptoms after the inappropriate antihypertensive therapy, and emphasized that the potent therapy might be unnecessary or harmful in the aged.
The prospective study on the antihypertensive therapy in patients above 60 years was carried out by the European Working Party on High blood pressure in the Elderly (EWPHE).7) They observed 25/10mmHg reduction of the blood pressure in 2 years in the absence of major electrolyte disturbances. But the terminating events were still being followed to prove the difference. Terasawa8) carried out the prospective study on 121 hypertensive patients in the aged. The incidences of cerebrovascular disease, congestive heart failure and myocardial infarction in 5 year period were 17.1% in the drug group and 31.4% in the placebo group showing no significant difference. The incidence of morbid events in the drug group was similar to the present results, but that of the placebo group was higher than our data probably due to the difference of protocol in treating cases with blood pressure elevation. Svardsudd et al9) followed up hypertensive patients of 50 years old for 13.5 years and concluded that hypertension accerelates cerebrovascular and cardiac events. The usefulness of antihypertensive treatment in mild hypertension was proved in the VA study in cases of diastolic blood pressure of 90 to 114mmHg.10) The incidence of morbid events was 11.8% in the drug group and 28.9% in the placebo group. When the cases terminated on account of elevated blood pressure in the placebo group were summed up with the morbid events, total assessable events reached 39.2%. Since the average ages in the VA study were 52.0 and 50.5 years, these effects were not applicable to the aged. However, the prevalences of morbid events were fairly similar to the present study in the aged. The VA study analysed the morbid events in different age gronps.11) The incidences of morbid events in the fifties were 8.7% in the treated group and 26.9% in the control group, and these incidences over the sixties were 28.9% and 62.9% respectively showing the effectiveness of antihypertensive treatment in the aged even in the group with lower diastolic pressure of 90 to 104mmHg.
The study by the Society of Actuaries concluded that more deaths could occur from untreated hypertension in the older population, and hypertensives with onset at age 35 had 15 excess death in the subsequent 20 years, but those with onset at age 55 had 25 excess death in the same interval.12) The USPHS study13) on the treatment of mild hypertension of younger population revealed no significant difference between the treated and control groups. The treatment of the mild hypertension in younger population should be directed to other risk factors or general health control. The mild hypertension in the aged should be treated, since the hypertension would trigger cardiovascular events on the basis of atherosclerosis of the target organs.
Systolic hypertension was frequently observed in the elderly, consisting 44% of the present subjects. Colandrea et al4) found that cardiovascular complications were more prevalent in systolic hypertension than in normotension in the aged of 69 years on average. Kannel et al5) revealed a positive relationship between systolic hypertension and cerebral infarction or coronary heart diseases, and emphasized the need for the treatment of systolic hypertension. Kuramoto et al14) found the atherosclerosis of cerebral and coronary arteries as well as cerebovascular and coronary complications in systolic hypertension to be similar to that in diastolic hypertension, and significantly different from normotensives in the aged.
On the basis of the present study we concluded that antihypertensive treatment in mild hypertension of the aged was effective to prevent cerebrovascular and cardiac events if the patients revealed normal activity of daily living and social activities.
However, the treatment should follow the stepped care approach15) with a small starting dosis, and should not lower the blood pressure abruptly.
The target level of blood pressure should be determined January, 1981 individually watching the general health condition of the patients. The blood pressure in the drug group of the present study reached around 150/80 mmHg. Taguchi and Freis16) repoted that the partial reduction of blood pressure in VA study was still effective in prevention of morbid events. The cardiovascular complications were of 14.9% and 9.7% in groups with posttreatment diastolic blood pressures of 90mmHg or higher and 80mmHg or less, and these attack rates were significantly less than the 28.9% of patients in the placebo group. The present study used a small amount of thiazide diuretics (trichlormethiazide 1 to 4mg) as a basal antihypertensive drug, and found no significant changes in potassium, uric acid, hematocrit and others. However, care should be taken on the electrolytes, blood sugar, uric acid, blood urea nitrogen, and hematocrit to prevent the specific side effect in the elderly. The morbid events in the elderly hypertension were not only cerebrovascular or cardiac complications but also other complications such as bone and joint diseases, cancer, infection, psychiatric disorder and others, and the other complications were 2 or 3 times more prevalent than the cerebrovascular or cardiac complications indicating the need for the general health ckeck up during the antihypertensive treatment.
